What is OrganOx?
OrganOx operates at the intersection of deeptech and life sciences, focusing on the development of innovative perfusion systems that redefine the standards of organ care. Originating as a spin-out from a leading academic institution, the company has transitioned into a high-growth enterprise-level entity. Its core technology addresses the critical shortage of viable donor organs by providing a controlled environment that maintains organ health during transport and storage. By enhancing the usability of donor organs, OrganOx is directly contributing to increased transplant success rates and improved patient survival, positioning itself as a critical infrastructure provider in the modern healthcare ecosystem.
How much funding has OrganOx raised?
OrganOx has raised a total of $174.6M across 2 funding rounds:
Private Equity
$32.6M
Other Financing Round
$142M
Private Equity (2023): $32.6M with participation from Lauxera Capital Partners
Other Financing Round (2025): $142M led by HealthQuest Capital, Lauxera Capital Partners, Avidity Partners, BGF, Soleus Capital, Sofina, Longwall Ventures, and University Of Oxford Department Of Physics
Key Investors in OrganOx
HealthQuest Capital
HealthQuest Capital provides growth capital to companies that are transforming healthcare through innovations in medical devices, technologies, healthcare services, and diagnostics.
Lauxera Capital Partners
Lauxera Capital Partners is an independent, international investment fund that focuses on growth companies in the Healthtech sector, specifically targeting early profitability stage businesses.
Soleus Capital
Soleus Capital is a healthcare investment firm that specializes in innovative life sciences sectors, including biotech, medtech, diagnostics, and genomics.
What's next for OrganOx?
With the recent infusion of capital, OrganOx is poised to enter a new phase of commercial expansion and technological refinement. The company's strategic roadmap likely involves scaling its manufacturing capabilities to meet rising demand for its perfusion systems while simultaneously investing in clinical research to broaden the scope of its applications. As the firm moves beyond its initial development stages, the focus will shift toward global market penetration and the integration of its systems into standard hospital protocols. By maintaining its commitment to scientific rigor and clinical efficacy, OrganOx is set to play a pivotal role in the future of transplantation medicine, potentially setting new benchmarks for organ preservation technology worldwide.
See full OrganOx company page
